Clascoterone: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Clascoterone: clinical details
Prescribing considerations
- For cutaneous use only; avoid damaged, eczematous or sunburnt skin and mucosal exposure.
- Large treated surface areas, prolonged use and occlusion may increase systemic absorption.
- Evidence in people aged 65 years and over is limited; use below age 12 is not established.
- Review concomitant topical products for cumulative irritation and ask about corticosteroid exposure.
Contraindications and cautions
- Hypersensitivity to clascoterone or any formulation excipient.
- Exercise caution where systemic absorption or concurrent HPA-axis suppression is a concern.
Monitoring
- Assess persistent or severe local reactions.
- Consider adrenal suppression if compatible symptoms develop; discontinue treatment if suppression is confirmed.
- Potassium elevation has been observed, although no routine laboratory-monitoring schedule is specified.
Clinical pharmacology
Clascoterone is a locally acting androgen-receptor inhibitor with low systemic exposure after cutaneous application. Cortexolone is a possible primary metabolite; human excretion has not been fully characterised.
Formulation and product differences
- The selected product is a white to almost-white homogeneous cream for external use.
- Cetyl alcohol may cause contact dermatitis; propylene glycol may cause skin irritation.
- After dispensing, store below 25°C and do not freeze. Follow the product instructions for disposal after dispensing or opening.
Clascoterone preparations and strengths
Cream
Route: Cutaneous
Strengths: 10 mg/g
Clascoterone interactions
Formal interaction studies, including studies with other topical treatments, have not been performed.
Topical or inhaled corticosteroids
Use cautiously because both treatments may suppress the hypothalamic–pituitary–adrenal axis.
Irritating or strongly drying topical products
Medicated or abrasive cleansers, alcohol-rich products and astringents may increase local irritation, so concurrent use should be limited.
Systemic medicines
Clinically meaningful pharmacokinetic interactions are not expected because systemic clascoterone exposure is very low.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.